Room Disinfection Technologies Compared: Fogging, UV-C and Vapourised Hydrogen Peroxide in Canada and the US

October 1, 2026

Portable examination table covered with a disposable non-woven sheet, representing a room surface that must be cleaned between patients

Three technologies are sold for the same job — reducing the microbial load on the surfaces of a room between patients — and they are not interchangeable. Fogging, ultraviolet-C emitters and vapourised hydrogen peroxide differ in how the agent reaches a surface, in whether the room has to be empty, in what the manufacturer can hand you as evidence, and in which regulator has jurisdiction over the product itself. This article compares the three across eight parameters and sets out the difference between a validated process and a machine that was purchased.

It is written for the facilities manager, infection control practitioner or procurement lead who has to justify a decision. Every performance statement below is attributed to a published source rather than to a supplier, and none of it is a claim about the effectiveness of any specific product in your building.

Quick facts

The three technologies differ in mechanism before they differ in price: fogging and vapourised hydrogen peroxide deliver a chemical to surfaces, while UV-C delivers radiation and is blocked by anything in its path.
Under United States federal rules, the antimicrobial chemistry and the device are regulated separately: the chemistry is registered by the Environmental Protection Agency, while a whole-room UV-C device can be regulated by the Food and Drug Administration as a Class II medical device.
The FDA classification for a whole room microbial reduction device defines it as reducing microbial load on medical device surfaces following cleaning and disinfection, and its target area as unoccupied rooms. Those two conditions are part of the category, not marketing language.
Public Health Ontario describes ultraviolet germicidal irradiation as used for surface and air disinfection in certain settings and states that it also has limitations and potential harms.
A validation report is not the same document as a specification sheet. The specification tells you what the unit is; the validation tells you what was measured, where, how many times, and what result was accepted.

What this article compares — and what it does not

This comparison covers equipment and processes: a fogging or dry-mist delivery system, a UV-C whole-room emitter, and a vapourised hydrogen peroxide cycle. It does not compare liquid disinfectant products, wipe formats or surface chemistry, which are covered separately in the article on hydrogen peroxide wipes in healthcare settings. The distinction matters because the buying questions are different. A wipe is selected on its label claim and contact time; a room system is selected on how its performance was demonstrated and on what happens to the room while it runs.

Disposable nitrile gloves worn while handling disinfectant chemicals and performing manual cleaning

Table 1 — Three technologies across eight parameters

Read each row as a question you will have to answer in a proposal review. Where a parameter depends on the specific formulation or model, the cell says so rather than generalising.

Parameter	Fogging / dry mist	UV-C whole-room emitter	Vapourised hydrogen peroxide
Mechanism	A chemical is dispersed as an aerosol or mist of liquid droplets	Radiation at germicidal wavelengths is emitted into the room	A chemical is delivered as a vapour; one documented form deposits as a microscopic film
Droplet or particle size	Varies by process; a source published by APIC, SHEA and AHE records one method producing particles around 1 micron and another in the 8–12 micron range	Not applicable — radiation, not particles	Not applicable — vapour
Distribution and shadowing	Depends on droplet settling; the same source notes the effect is primarily on horizontal surfaces, and manufacturers are asked to state how high-touch surfaces out of the direct path are reached	Radiation is limited by distance, angle of incidence and shadowing, and by the texture of the target surface	Vapour disperses through the room; the room must be sealed for the cycle
Room must be empty	Yes in practice — the space has to be vacated and then cleared before re-entry	Yes; the FDA category specifies unoccupied rooms	Yes; the source records that it is unsafe to enter until the vapour clears to a safe level
Cleaning before the cycle	Cleaning is described as the first and most important step, and normal room cleaning is still required even when a room decontamination process is used	The FDA category is defined as reducing microbial load following cleaning and disinfection	Documented for dry, pre-cleaned, non-porous exposed surfaces
Cycle time	Product-dependent; the published discussion describes vapour or mist clearance for some formulations taking up to three to four hours, against roughly 35–40 minutes for routine cleaning	Product-dependent; cycle length is set by the dose delivered at the furthest point to be treated	Product-dependent; the same discussion places the principal time cost in clearance rather than in the active phase
Material compatibility	Must be assessed against the formulation and the equipment in the room	Radiation exposure is a function of the cycle; sensitive materials must be assessed	Must be assessed; the published guidance explicitly asks manufacturers to state adverse effects on medical devices and sensitive equipment
How performance is evidenced	Product-dependent; the published discussion notes that standardised test methods for vapour and dry-mist application were still needed	Carrier-based testing: inoculated carriers placed and oriented through a simulated room is described as the appropriate means of validating a UV-C system	Product-dependent; sterilisers and sterilization processes are validated against published standards

Two rows in that table do the heaviest work. The first is room must be empty. A technology that requires the room to be vacated is a different operational asset from one that runs while the room is in use, and the cost of that constraint is measured in bed-days, operating-room turnaround or appointment slots, not in equipment price. The second is cleaning before the cycle. None of the three replaces manual cleaning; the FDA category builds it in, and the professional bodies that wrote to the EPA about fogging stated that normal room cleaning is still required even when a room decontamination process is used.

Table 2 — Regulatory status is different for the chemistry and for the device

This is the table that most often decides a cross-border purchase, because a supplier's home-market registration does not travel with the product.

Topic	Fogging / dry mist	UV-C whole-room emitter	Vapourised hydrogen peroxide
United States — what is regulated	The antimicrobial chemistry, registered by the EPA under the Federal Insecticide, Fungicide, and Rodenticide Act	The device, which can be regulated by the FDA as a medical device	The sterilant chemistry is registered by the EPA; the process equipment is regulated as equipment
United States — example designation	An EPA registration number for the chemistry; the delivery equipment is generally not a regulated medical device	Product code QXJ, regulation number 880.6510, device class 2, submission type 510(k)	An EPA registration number for the sterilant
Condition stated in the designation	Set by the registered label	The category defines the target area as unoccupied rooms and the action as reduction of microbial load on medical device surfaces following cleaning and disinfection	Set by the registered label and by the validated process
Canada — where to look	A disinfectant placed on the market carries its own registration number; the equipment is not licensed as a device	A device that carries a medical claim generally requires a device licence, and the establishment that imports or distributes devices requires an establishment licence	Same split: the chemistry and the process equipment are treated differently
What the Canadian instrument does not tell you	Nothing about the performance of a specific unit in a specific room	An establishment licence says nothing about the performance of any individual device	Nothing about the performance of the cycle in your room

The practical reading is short. In the United States, a supplier of fogging equipment may present an EPA registration number that belongs to the chemistry, not to the machine. A supplier of a UV-C room system may present a 510(k) clearance that does belong to the device — and that clearance will describe the conditions under which the device is intended to be used, including the state of the room. In Canada, the establishment licence number that a distributor prints on its paperwork is issued to the establishment, not to the product, which is why it cannot be used as evidence of performance.

How does fogging or dry mist reach a surface?

Fogging is the technology with the longest and most contested public history, and the record is worth knowing because it still shapes institutional policy. When APIC, SHEA and the Association for the Healthcare Environment responded to the EPA on fogging in 2011, they noted that the Centers for Disease Control and Prevention guidelines of 2003 and 2008 did not support fogging, and that the 2008 guideline stated that disinfectant fogging should not be performed for routine purposes in patient-care areas. They also noted the reason: the studies behind those recommendations involved chemistries — formaldehyde, phenol-based agents and quaternary ammonium compounds — that are no longer used for this application and were associated with adverse effects on staff.

The same letter drew a boundary that any current buyer should reproduce in their own evaluation. The authors recorded that neither vaporised hydrogen peroxide nor any other specific disinfectant had been shown to reduce the incidence of endemic healthcare-associated infections using methods scored as having moderate or high quality, and that most of the evidence involved in-vitro log reduction or observational studies conducted during outbreaks. They also noted that surfaces are repopulated within 24 to 48 hours of re-occupancy by patients and staff. None of that makes the technology useless — it makes the claim you can honestly make about it narrower than a sales sheet suggests.

Two operational facts from that same source belong in any business case for fogging. Room preparation matters: the room has to be sealed, and the vapour must clear before re-entry. And the time cost is real, with the published discussion describing clearance for some formulations taking up to three to four hours against roughly 35 to 40 minutes for routine cleaning and disinfection.

How is a UV-C whole-room system evidenced?

UV-C is the only one of the three that is regulated in the United States as a medical device in its own right. The FDA product classification for a whole room microbial reduction device — product code QXJ, regulation number 880.6510, device class 2 — defines the device as reducing microbial load on medical device surfaces following cleaning and disinfection, using a remotely operated germicidal device, with a target area of unoccupied rooms. A 510(k) clearance issued under that code therefore carries the conditions of use with it, and those conditions are a fair summary of the technology's boundary: the room is empty, and cleaning has already happened.

The technical limitation is physical rather than commercial. A 2021 paper published in the Journal of Research of the National Institute of Standards and Technology records that the relationship between dosimetry and germicidal effect is affected by the inherent limitations of UV-C with respect to distance, angle of incidence and shadowing, as well as the texture of the target surface. Shadowing is the reason a UV-C cycle is specified by placement rather than by duration alone: a surface behind an obstruction receives a different dose from one in the direct path, no matter how long the emitter runs.

The same paper is the most useful document available on how a UV-C system should be evidenced, and it is written as a set of recommendations for future standards. It states that reductions of inoculated bacteria on carriers is the appropriate method of validating a UV-C-emitting system, and recommends a defined set of carrier materials matching the real surfaces being tested, carriers placed both horizontally on horizontal surfaces and vertically on vertical surfaces, at least some carriers placed on the floor including beneath the emitter, and multiple carriers on furnishings with an emphasis on commonly touched items. It also notes that the carrier counts used for chemical disinfectant standards do not translate to UV-C.

That is what a validation report for a UV-C system should look like. A room photograph, a cycle time and a log reduction figure on a single slide is not a validation; it is a demonstration.

Public Health Ontario's ultraviolet disinfection resource describes ultraviolet germicidal irradiation as used for surface and air disinfection in certain settings, including healthcare environments, and states plainly that it has limitations and potential harms. In Canada that page — rather than a vendor brochure — is the reasonable starting point for a policy discussion.

What makes a vapourised hydrogen peroxide cycle validated?

Vapourised hydrogen peroxide sits between the other two. Like fogging, it delivers a chemistry and requires a sealed, unoccupied room. Like a device-regulated technology, it is validated as a process, which means the performance evidence is a cycle development document rather than a label claim.

The international framework for that evidence is the sterilization standards family. ISO 14937 sets out general requirements for the characterisation of a sterilizing agent and for the development, validation and routine monitoring and control of a sterilization process for medical devices. Applying that structure to a room cycle produces the documents a buyer should ask for: the cycle parameters that were established, the challenge devices and their placement, the acceptance criteria, the results, and the routine monitoring that will be repeated at intervals after the validation.

Monitoring is where the chain closes. A validated cycle and a routinely monitored cycle are two different states, and the monitoring formats used for vapour processes are described in the article on biological indicator standards for steam, ethylene oxide and vapourised hydrogen peroxide. Sensor and instrumentation choices for those cycles are covered in the article on hydrogen peroxide sensors and cycle validation monitoring.

Table 3 — What each document actually proves

Document	What it is evidence of	What it is not evidence of
Specification sheet	What the unit is rated to do under stated conditions	That it performed in your room
EPA registration number (chemistry)	That the chemistry is registered for the stated use	That the delivery equipment is regulated, or that a cycle in your room achieves a result
FDA 510(k) clearance (UV-C device)	That the device is cleared under a classification which itself states the cleaning and occupancy conditions	That a cycle in a specific room achieved a specific reduction
Validation report	What was measured, where, how many samples, and the result that was accepted	That the same result repeats without routine monitoring
Routine monitoring record	That the validated state was maintained over time	That the process is safe for every material in the room

The single sentence that separates a validated programme from a purchase is this: a validation is a study of a room, and a room is not a product. Two identical units in two differently shaped rooms with different furnishings and different degrees of clutter will not deliver the same result, which is why the evidence has to be regenerated on site.

How do you compare two room-disinfection proposals?

Six questions, asked in this order, resolve most of the ambiguity before a purchase order is raised:

Which room, and at which points in that room, was the performance measured?
How many sample locations were used, and were they placed before or after the proposed installation?
What cleaning step precedes the cycle, and is that step written into the protocol you will follow?
What is the re-entry procedure, and how does the operator know the room is safe to enter?
Which materials in the room were assessed for compatibility, and who confirmed that assessment?
What monitoring will be repeated after the initial validation, and where is the record kept?

Facilities running a disinfection programme alongside a sterilization workflow can start from the sterilization compliance hub, which collects the reprocessing and monitoring material, and from the cleaning and disinfecting collection. Teams that need to document a validated process should look at the cleanroom disinfection qualification comparison for Canadian and US pharmaceutical settings, which works through the same evidence question in a regulated manufacturing context. Consumables that support the workflow — protective equipment for staff handling chemistries, and the monitoring supplies that record a cycle — are grouped in the clinic supplies collection. Clinics evaluating monitoring formats can start from the biological indicator 5-pack trial; facilities ordering protective consumables at case level can use the heavy-duty nitrile gloves and the sterilization pouch range as reference points, and move to the wholesale account page or the b2b wholesale collection for case-level ordering.

CliniEco Medical supplies sterilization monitoring and protective consumables for Canadian care settings (MDEL #35334). This article compares published regulatory classifications and published technical guidance for third-party technologies. It makes no claim about the effectiveness of any specific product, and it is not a substitute for the equipment manufacturer's instructions for use or for your own validation.

Frequently Asked Questions

Is fogging the same thing as vapourised hydrogen peroxide?

No. Both deliver an agent to a sealed room, but the physical form differs, and the difference is measurable. The APIC, SHEA and AHE response to the EPA records one process producing particles in the range of about 1 micron and another in the range of 8 to 12 microns, which is part of why the terminology — fog, mist, vapour, fumigant — is not settled. For procurement, the practical consequence is that the two methods carry different cycle times, different clearance procedures and different material-compatibility questions.

Does a UV-C device kill everything in the room?

No technology should be assessed that way, and the reason is geometric. A NIST journal paper records that the relationship between measured dose and germicidal effect is affected by distance, angle of incidence and shadowing, and by the texture of the surface. A surface in the shadow of an obstruction receives less radiation than one in the direct path, which is why a UV-C cycle has to be defined by where carriers are placed, not only by how long the emitter runs.

Why does the FDA classification mention unoccupied rooms?

Because the classification is the definition of the technology's intended conditions of use rather than a marketing claim. The classification for a whole room microbial reduction device specifies a target area of unoccupied rooms and defines the action as reducing microbial load on medical device surfaces following cleaning and disinfection. A supplier presenting a clearance under that code is presenting those conditions with it.

Can a room-disinfection cycle replace manual cleaning?

No. The FDA classification for the device category builds cleaning and disinfection in as a preceding step, and the professional bodies that responded to the EPA on fogging stated that normal room cleaning is still required even when a room decontamination process is used, describing cleaning as the first and most important step. A cycle that is run instead of cleaning is being run outside the conditions its own documentation assumes.

What is the difference between a validation and a specification sheet?

A specification sheet describes the unit under stated conditions; a validation describes a study of a specific room, stating where samples were placed, how many were used, and which result was accepted. The specification can be transferred between sites; the validation cannot. If a proposal contains a specification sheet and a cycle time but no carrier or sample placement map, the evidence has not yet been produced.

How long does a vapour or mist cycle take, and why does that matter commercially?

It varies by product. In the published discussion of fogging and vapourised hydrogen peroxide, routine cleaning and disinfection of a room after discharge is placed at roughly 35 to 40 minutes, while clearance of the vapour for some formulations is described as taking up to three to four hours. Whether that is acceptable is an operational question about bed-days, theatre turnaround or appointment capacity rather than a clinical one, which is why the time cost belongs in the business case rather than in the appendix.